Genetic Counseling, VUS Interpretation, and Cost Navigation

Ordering the right genetic test is only half the work. The other half is the surrounding practice — pre-test counseling, interpretation of variants of uncertain significance (VUS), reanalysis of stored sequencing data, cost and insurance navigation, sponsored testing programs, and ongoing advances in the field. This page covers those practical considerations.

🔹 Bottom Line: Practical Considerations

Pre-test genetic counseling is mandatory for predictive / pre-symptomatic testing in asymptomatic at-risk relatives (HD, familial AD, familial FTD, familial ALS).
VUS is NOT a diagnosis. Counsel families clearly; request reanalysis every 2–3 years — 20–30% of VUSs are reclassified over 5 years.
ACMG variant classification (5-tier: pathogenic / likely pathogenic / VUS / likely benign / benign) is the standard.
Trio sequencing (proband + both parents) substantially increases yield — especially for de novo and recessive disease.
Cost varies widely; sponsored / no-charge programs exist for many neurologic conditions (ALS, SMA, CMT, HSP, ataxia, epilepsy, Fabry, Pompe).
Treatment-driven testing (SOD1, SMN1, DMD, TTR, GLA) should be ordered early — result changes therapy eligibility.
Long-read sequencing, RNA-seq reflex, and trio WGS are reshaping the diagnostic landscape — particularly for unsolved cases.

Pre-Test Genetic Counseling

When Counseling Is Mandatory

Predictive / pre-symptomatic testing in asymptomatic at-risk relatives of patients with autosomal dominant adult-onset progressive disease:
- Huntington disease.
- Familial Alzheimer disease (APP, PSEN1, PSEN2).
- Familial FTD (MAPT, GRN, C9orf72).
- Familial ALS (SOD1, C9orf72, others).
- Hereditary cancer syndromes with neurologic manifestations (NF1, NF2, TSC, VHL).
- Familial prion disease (PRNP).
Reproductive testing — carrier status, preimplantation genetic testing, prenatal diagnosis.

The HD Predictive Testing Protocol

The standard for predictive testing was set by the international HD predictive testing protocol — adopted broadly for other autosomal dominant adult-onset diseases:

Pre-test counseling × 2 sessions in person — discussion of the disease, implications of positive and negative results, decision support.
Mental health screening — pre-existing depression / anxiety / suicidality affect timing and support needs.
Cooling-off period before sample collection.
Result disclosure in person with immediate counselor support.
Post-test follow-up — weeks and months after disclosure; longer-term follow-up for positive results.

When Brief Counseling Is Appropriate

Symptomatic diagnostic testing: brief informed-consent counseling discussing what the test detects, what a positive / negative / VUS result would mean, and family implications.
Reproductive carrier testing in established couples without strong family history.

What Counseling Covers

Nature of the disease and inheritance pattern.
What the test detects and what it cannot detect.
Possible result categories: pathogenic, likely pathogenic, VUS, likely benign, benign, negative.
Implications for the patient (treatment, prognosis, monitoring).
Implications for family members (cascade testing, reproductive planning).
Insurance considerations and GINA protections (US — Genetic Information Nondiscrimination Act — applies to health insurance and employment but NOT life, disability, or long-term care insurance).
Emotional support resources.

Variant Classification (ACMG / AMP Guidelines)

The American College of Medical Genetics and Association for Molecular Pathology (ACMG/AMP) 2015 guidelines define a 5-tier classification used by most US clinical labs.

Classification	Meaning	Clinical action
Pathogenic	Causes disease — strong evidence	Confirmed diagnosis; cascade family testing
Likely pathogenic	Probably causes disease — strong but not definitive	Treat as diagnostic; cascade family testing with caveat
Variant of uncertain significance (VUS)	Cannot determine pathogenicity with current evidence	NOT a diagnosis; reanalyze in 2–3 years; do not treat based on VUS alone
Likely benign	Probably does not cause disease	Disregard clinically
Benign	Does not cause disease — strong evidence	Disregard

Variants of Uncertain Significance (VUS)

How Common Are They?

VUS reporting rate varies by test scope: ~10% of multi-gene panels, ~25–40% of WES, more for WGS.
Common in understudied populations (smaller reference datasets); efforts ongoing to address.

How to Counsel Families About a VUS

A VUS is not a diagnosis. The variant may or may not be related to the patient’s symptoms.
Treatment, surveillance, and family cascade testing should NOT be based on a VUS alone.
Ask the laboratory to reanalyze the variant every 2–3 years — clinical labs routinely reclassify variants as new evidence accumulates.
Estimated 20–30% of WES VUSs change classification over 5 years — either upgraded to likely pathogenic or downgraded to benign.

Steps That Can Help Reclassify a VUS

Parental testing: if a VUS is found in a recessive disease with one known pathogenic variant in trans, testing the parents establishes whether the VUS is in cis or trans with the known variant.
Segregation analysis: if the VUS segregates with disease in a multi-generation family, this is evidence for pathogenicity.
Functional studies at specialized centers can sometimes resolve VUSs.
Database deposition: submitting the variant to ClinVar with phenotype data helps the field reclassify variants over time.

🔹 Clinical Relevance: How to Talk to a Family About a VUS

“The lab found a change in the NOTCH3 gene, but we don’t yet have enough information to know whether this change is causing your symptoms or not. We call this a ‘variant of uncertain significance.’ This is NOT a diagnosis. We will NOT change your treatment based on this finding alone, and we will NOT recommend that your family members get tested for this variant yet. We will ask the lab to recheck the variant in 2–3 years — over time, many of these are reclassified as either harmless or disease-causing as more people are tested.”

Common pitfalls:

Don’t tell a patient they “have” a disease based on a VUS.
Don’t initiate cascade family testing for a VUS.
Don’t change therapy based on a VUS.
Do document the VUS, the disease being considered, and the plan to reanalyze.

Trio Sequencing (Proband + Both Parents)

Why Trio Increases Yield

Identifies de novo variants (proband variant absent from both parents) — strong evidence for pathogenicity.
Resolves compound heterozygosity (variants on different parental alleles — true biallelic disease).
Clarifies inheritance pattern when the family history is ambiguous.
Reduces VUS burden by identifying which variants are likely benign (inherited from unaffected parents).

When to Order Trio

Pediatric undiagnosed disease.
Epileptic encephalopathy.
Intellectual disability + neurologic symptoms.
Multiple congenital anomalies.
Suspected de novo or recessive disease.

When Singleton Is Acceptable

Parents unavailable.
Adult-onset disease where parental phenotype is known and parents are unaffected (de novo variant suspected).
Strong autosomal dominant phenotype where the inheritance is unambiguous.

Cost & Insurance Navigation

Typical Cost Tiers

Single-gene Sanger: US $200–600. Usually covered for symptomatic patients.
Multi-gene NGS panel: US $1,000–3,000. Usually covered with pre-authorization.
WES: US $3,000–6,000. Often requires documented prior negative testing.
WGS: US $4,000–10,000+. Rarely covered as first-line outside specialized programs.
Mitochondrial testing in muscle: requires biopsy + tissue handling — coordinate with neuromuscular center.

Insurance & GINA

GINA (Genetic Information Nondiscrimination Act, 2008) protects against discrimination by health insurance and employers based on genetic information.
GINA does NOT extend to: life insurance, disability insurance, long-term care insurance.
Counsel patients to consider these before genetic testing if those policies are not in place — purchasing some types of policies before testing may be advisable.

Reproductive & Family Implications

A positive genetic diagnosis often affects family members — facilitate cascade testing of at-risk relatives after appropriate counseling.
Reproductive options once the familial variant is known:
- Preimplantation genetic testing for monogenic disease (PGT-M).
- Prenatal diagnostic testing (CVS or amniocentesis).
- Use of donor gametes.
- Adoption.
Expanded carrier screening for recessive conditions is increasingly common before pregnancy.

Recent Advances & What’s Changing

Long-Read Sequencing

PacBio HiFi and Oxford Nanopore are becoming first-line for some loci:
- FXN GAA (Friedreich ataxia).
- RFC1 AAGGG (CANVAS).
- Complex repeat-expansion disorders.
Long-read accuracy now exceeds the older Southern blot + RP-PCR combination for sizing.
Methylation calling on the same molecule extends utility to imprinting disorders.

WGS as First-Line in Pediatric Undiagnosed Disease

Programs like Genomics England’s 100,000 Genomes Project and NICUSeq show diagnostic yields of 25–40% in undifferentiated severe pediatric disease.
WGS detects coding + non-coding + structural variants + mtDNA in one test.
Cost is dropping; insurance coverage improving in some markets.

RNA Sequencing as Reflex to WES

Adding RNA-seq to WES-negative cases identifies splice-altering and deep-intronic variants that DNA sequencing alone misses.
Yield: 8–35% additional diagnoses in undiagnosed cohorts.
Especially valuable for unsolved leukodystrophy / muscle disease / metabolic disease cases.

Polygenic Risk Scores (PRS)

For late-onset multifactorial disease (AD, PD, MS, stroke).
Clinically informative but not diagnostic.
Risk estimates depend on ancestry-matched reference data — currently performs worse in non-European-ancestry populations.
Counsel cautiously.

Treatment-Driven Testing Expansion

The list of treatable genetic neurologic diseases grows yearly: SOD1-ALS (tofersen), SMA (nusinersen / risdiplam / onasemnogene), DMD (exon-skipping), hATTR (patisiran / vutrisiran / tafamidis), Fabry (chaperone migalastat), Friedreich ataxia (omaveloxolone), Pompe (alglucosidase alfa, cipaglucosidase alfa).
Order the test even when phenotype is provisional — confirming the genetic diagnosis unlocks therapy.

Newborn Genome Sequencing

Pilot programs (BabyBeacon, NSIGHT, Generation Study UK) are evaluating broader newborn genome sequencing.
Early data suggest feasibility at scale; ethical and counseling frameworks still evolving.
Likely to expand newborn screening beyond current enzymatic panels.

🔹 Clinical Relevance: Re-Engage With Stored Sequencing Data

If a patient had WES or WGS several years ago and remains undiagnosed, request reanalysis of the stored data:

New disease genes are identified continually — variants previously classed as VUS in unstudied genes may now be pathogenic.
Updated ACMG criteria may reclassify previously borderline variants.
RNA-seq reflex on WES-negative cases adds 8–35% diagnostic yield.
Cost is minimal vs. ordering new sequencing — many labs offer reanalysis at substantially reduced or no cost.

Build reanalysis into the long-term care plan for undiagnosed genetic disease patients — schedule every 2–3 years.

Pitfalls and Pearls

Pre-test counseling is mandatory for predictive testing (HD, familial AD, familial FTD, familial ALS).
VUS is NOT a diagnosis — counsel clearly; don’t change treatment or family screening based on VUS alone.
Reanalyze stored sequencing every 2–3 years — 20–30% of VUSs are reclassified over 5 years.
Trio sequencing increases yield for de novo and recessive disease; offer when parents are available.
Sponsored testing programs are widely available — check before paying out-of-pocket.
GINA protects against health insurance and employment discrimination but NOT life, disability, or long-term care.
ACMG 5-tier classification is the standard; understand pathogenic / likely pathogenic / VUS / likely benign / benign.
Long-read sequencing is now first-line for FXN, RFC1, and other complex loci.
RNA-seq reflex adds 8–35% diagnostic yield to WES-negative cases.
Treatment-driven testing should be ordered early — result changes therapy eligibility.
Carrier screening + reproductive options are part of the conversation once a familial variant is identified.

References

Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants (ACMG/AMP). Genet Med. 2015;17(5):405-424.
Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19(2):192-203.
Smith HS, Swint JM, Lalani SR, et al. Clinical application of genome and exome sequencing as a diagnostic tool for pediatric patients. Genet Med. 2019;21(1):3-16.
Tafazoli A, Khalili M, Ranjbar V, et al. Long-read sequencing in neurogenetic disorders: a review. Mov Disord Clin Pract. 2024;11(3):236-251.
Cummings BB, Marshall JL, Tukiainen T, et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med. 2017;9(386):eaal5209.
Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. Lancet. 2019;393(10173):758-767.
HD Predictive Testing Protocol — International Huntington Association & World Federation of Neurology Research Group on Huntington’s Chorea. J Med Genet. 1994;31(7):555-559.